Received Jan 7, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Z014438 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Z011893 | — |
The patient and/or their guardian have not reported any other adverse issues or side effects related to the administration of the vaccines.; A nurse called to report the inadvertent administration of VARIVAX and PROQUAD to a patient on 12/29/2025 instead of VARIVAX and MMR II as ordered.; A nurse called to report the inadvertent administration of VARIVAX and PROQUAD to a patient on 12/29/2025 instead of VARIVAX and MMR II as ordered.; Information has been received from Business Partner. This Spontaneous report was received from Other health professional and referred to a/an 1 -year-old Male patient. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On 29-Dec-2025, the patient started therapy with sterile diluent Solution for injection Unknown Batch/Lot Number (Dose Text: unknown). On 29-Dec-2025, the patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection (0.50 mL) (total) (Batch/Lot Number: Z011893) (Expiration date: 17-Jul-2027) dose form was Injection (Dose Text: 0.5mL/once). On 29-Dec-2025, the patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection (0.50 mL) (total) (Batch/Lot Number: Z014438) (Expiration date: 11-Mar-2027) dose form was Injection (Dose Text: 0.5mL/once). At the time of the Event´s occurrence, the patient was not started on Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection. The patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection for the treatment of prophylaxis, The patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection for the treatment of prophylaxis, On 29-Dec-2025, the patient experienced A nurse called to report the inadvertent administration of VARIVAX and PROQUAD to a patient on 12/29/2025 instead of VARIVAX and MMR II as ordered. (Wrong product administered). On 29-Dec-2025, the patient experienced A nurse called to report the inadvertent administration of VARIVAX and PROQUAD to a patient on 12/29/2025 instead of VARIVAX and MMR II as ordered. (Overdose). On an unknown date, the patient experienced The patient and/or their guardian have not reported any other adverse issues or side effects related to the administration of the vaccines. (No adverse event). The Outcome of Overdose was not provided. The Outcome of No adverse event was not provided. The Outcome of Wrong product administered was not provided. The action taken with sterile diluent Solution for injection regarding Overdose with Not Applicable dechallenge and rechallenge results. The action taken with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection regarding Overdose was Not applicable with Not Applicable dechallenge and rechallenge results. The action taken with Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection regarding Overdose was Not applicable with Not Applicable dechallenge and rechallenge results. The action taken with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection regarding Overdose was Not applicable with Not Applicable dechallenge and rechallenge results. Case Assessments: Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection regarding Wrong product administered with Not Applicable dechallenge and rechallenge results. Case Assessments: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection regarding Wrong product administered with Not Applicable dechallenge and rechallenge results. Case Assessments: Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection regarding No adverse event with Not Applicable dechallenge and rechallenge results. Case Assessments: Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection regarding Wrong product administered with Not Applicable dechallenge and rechallenge results. Case Assessments: sterile diluent Solution for injection regarding No adverse event with Not Applicable dechallenge and rechallenge results. Case Assessments: sterile diluent Solution for injection regarding Wrong product administered with Not Applicable dechallenge and rechallenge results. Case Assessments: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection regarding No adverse event with Not Applicable dechallenge and rechallenge results. Case Assessments: Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection regarding No adverse event with Not Applicable dechallenge and rechallenge results. The Other health professional considered the event Overdose (,) to be not assessed to sterile diluent Solution for injection, the event Overdose (,) to be not assessed to Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection, the event Wrong product administered (,) to be not assessed to Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection, the event Wrong product administered (,) to be not assessed to Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection, the event No adverse event (,) to be not assessed to Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection, the event Overdose (,) to be not assessed to Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection, the event Wrong product administered (,) to be not assessed to Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection, the event No adverse event (,) to be not assessed to sterile diluent Solution for injection, the event Wrong product administered (,) to be not assessed to sterile diluent Solution for injection, the event No adverse event (,) to be not assessed to Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate and solvent for solution for injection, the event Overdose (,) to be not assessed to Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection, and the event No adverse event (,) to be not assessed to Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection The Other health professional considered the event No adverse event to be non-serious, the event Wrong product administered to be non-serious, and the event Overdose to be non-serious
Sterile diluent